Abstract: Disclosed herein are compounds, compositions, formulations, and methods for modulating the A2B adenosine receptor in combination with immune checkpoint inhibitors in mammals with cancer.

Abstract: Provided are a protection circuit for a brushless DC motor, and a control device. The protection circuit is applied to a control device for a brushless DC motor, the control device including a main control chip and a protection circuit for driving a brushless DC motor. The protection circuit includes a sampling signal input end (RNF), a first resistor (R1), a first capacitor (C1), a second capacitor (C2), a comparator (IC2) and a switching element (IC1), connected together in a preset structure.

Abstract: Provided are a protection circuit for a brushless DC motor, and a control device. The protection circuit is applied to a control device for a brushless DC motor, the control device including a main control chip and a protection circuit for driving a brushless DC motor. The protection circuit includes a sampling signal input end (RNF), a first resistor (R1), a first capacitor (C1), a second capacitor (C2), a comparator (IC2) and a switching element (IC1), connected together in a preset structure.

Abstract: Provided herein are methods that relate to a novel therapeutic strategy for treatment of heart and/or cardiovascular diseases. The method includes administration of LOXL2 inhibitors for treating, preventing, or ameliorating at least one symptom associated with heart and/or cardiovascular diseases.

Abstract: Provided herein are methods that relate to a novel therapeutic strategy for treatment of heart and/or cardiovascular diseases. The method includes administration of LOXL2 inhibitors for treating, preventing, or ameliorating at least one symptom associated with heart and/or cardiovascular diseases.

Abstract: Method of treating and/or preventing pulmonary arterial hypertension comprising administering effective amounts of ambrisentan or a pharmaceutically acceptable salt thereof and riociguat or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to method of treating arrhythmias or heart failure comprising co-administration of a late INa inhibitor and a CAMK II inhibitor.

Abstract: Disclosed are novel isoflavone derivatives having the structure of Formula I which are useful as ALDH-2 inhibitors for treating mammals for dependence upon drugs of addiction, for example addiction to dopamine-producing agent such as cocaine, morphine, amphetamines, nicotine, and alcohol.

Abstract: Disclosed are novel isoflavone derivatives having the structure of Formula I which are useful as ALDH-2 inhibitors for treating mammals for dependence upon drugs of addiction, for example addiction to dopamine-producing agent such as cocaine, morphine, amphetamines, nicotine, and alcohol.

Abstract: This invention pertains to the discovery that a dopamine receptor agonist can activate PKA signaling and/or can act synergistically with an adenosine receptor to activate such signaling. In various embodiments, this invention exploits the synergy between the dopamine receptor pathway and an adenosine receptor pathway to provide methods of mitigating one or more symptoms produced by the chronic consumption of a substance of abuse or to mitigate one or more physiological and/or behavioral symptoms associated with cessation of chronic consumption of a substance of abuse. In certain embodiments, the methods involve administering to the mammal an effective amount of an adenosine receptor antagonist; and an effective amount of a dopamine receptor antagonist; where the effective amount of the adenosine receptor antagonist is lower than the effective amount of an adenosine receptor antagonist administered without said dopamine receptor antagonist.

Abstract: Disclosed are novel isoflavone derivatives having the structure of Formula I which are useful as ALDH-2 inhibitors for treating mammals for dependence upon drugs of addiction, for example addiction to dopamine-producing agent such as cocaine, morphine, amphetamines, nicotine, and alcohol.

Abstract: Disclosed are novel isoflavone derivatives having the structure of Formula I which are useful as ALDH-2 inhibitors for treating mammals for dependence upon drugs of addiction, for example addiction to dopamine-producing agent such as cocaine, morphine, amphetamines, nicotine, and alcohol.